Month: May 2024
– In a multiple-ascending dose (MAD) study in patients with asthma, up to 54% reduction in fractional exhaled nitric oxide concentration (FENO) was observed with administration of verekitug, with treatment effects sustained up to 24 weeks after last dose – – Verekitug displayed a favorable safety and tolerability profile without evidence of clinically meaningful immunogenicity…
Read More
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week KT-621 expected to start Phase 1 in the second half of 2024,with Phase…
Read More
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 Excerpt from the Press Release: PHILADELPHIA, May 16, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the…
Read More
May 16, 2024 at 7:00 AM EDT Excerpt from the Press Release: CARLSBAD, Calif., May 16, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome. ION582 was safe and well tolerated in the study and showed encouraging and consistent benefits…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today detailed data presented by its partners at the University of California, San Francisco (UCSF) on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate,…
Read More
– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70% achieved >15% and 45% achieved >20% weight loss – – In a subgroup with…
Read More
Five pharmaceutical partners start testing immunotherapies on human models created from immune organoids at population scale Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies…
Read More
Excerpt from the Press Release: SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ — NeuShen Therapeutics (the “Company”), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer in Australia in the Phase I first-in-human clinical trial of NS-136, a novel selective…
Read More